Optibrium and Collaborative Drug Discovery partner on integration of StarDrop with CDD Vault
Collaboration provides a comprehensive platform for data management, analysis and compound design in drug discovery.
Optibrium and Collaborative Drug Discovery (CDD), developers of software products and services for drug discovery and development, are collaborating to integrate the StarDrop and CDD Vault platforms. This creates a seamless connection in real time between project data, securely held and managed in CDD Vault, and StarDrop’s unique compound design and optimisation capabilities. Instant access to the latest assay and compound data, with which a project team can share, interpret and model their chemistry, will lead to better decisions and shorter project timelines.
CDD Vault is a hosted biological and chemical database that securely manages project data. It allows researchers, across academic laboratories, research foundations, as well as small and large companies, to intuitively organise chemical structures and biological study data. CDD Vault supports a unique collaborative model that enables data to be safely shared with internal or external partners through an easy-to-use web interface.
Researchers can now seamlessly retrieve their biological results from CDD Vault using an intuitive search interface within StarDrop that enables users to easily run CDD Vault queries, returning the results directly in StarDrop. This extension to StarDrop is available free of charge to existing StarDrop and CDD Vault users, providing a highly visual way to interpret these data and their relationships with compound structures, clearly highlighting the best chemistries and multi-parameter optimisation strategies for drug discovery.
Dr Matthew Segall, CEO of Optibrium, commented: “When selecting compounds the importance of working with the most up-to-date data can’t be over stated – incomplete or out-of-date information results in time and effort being wasted. With this in mind, our aim is for StarDrop to fully integrate with the very ‘best in class’ drug discovery informatics platforms and we are delighted to be working with CDD to support drug discovery project teams to make good decisions and achieve their optimisation goals faster.”
Dr Barry Bunin, CEO CDD, added: “CDD understands that efficiency in modern drug discovery is a function of how well the industry's thought leaders work together. To that end, we are delighted to collaborate with Optibrium through this integration between StarDrop and CDD Vault. CDD Vault is particularly strong for project teams working across disciplines and, when coupled with StarDrop's unique ability to help scientists make confident and objective decisions, will undoubtedly help drug discovery project teams manage, analyze, and present chemical structures and biological assay data."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.